Johnson & Johnson (JNJ) financial statements and ratios from SEC XBRL: revenue $97.9B (TTM), net margin 28.5%, revenue growth 6.6% YoY, P/E 30.6. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $94.19B |
| Revenue (TTM) | $97.9B |
| Net Margin | 28.5% |
| Return on Equity | 24.8% |
| Operating Margin (TTM) | 29.6% |
| Debt / Equity | 0.58 |
| Current Ratio | 1.09 |
| Net Debt / EBITDA | 1.1 |
| Interest Coverage | 40.7 |
| Revenue Growth (YoY) | 6.6% |
| EPS Growth (YoY) | 0.0% |
| FCF Growth (YoY) | 157.3% |
| P/E Ratio | 30.6 |
| EV / EBITDA | 22.8 |
| Price / Book | 7.57 |
| Price / Sales | 6.57 |
| FCF Yield | 3.5% |
| Piotroski F-Score | 3/9 |
| Piotroski checks passed | 3 of 9 |
| Industry P/E (Pharmaceutical Products) | 15.0 |
| Sector P/E (Healthcare) | 20.7 |
JNJ overview · JNJ earnings · JNJ KPIs · JNJ documents · JNJ ownership · JNJ peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.